Print this page

EULAR 2024 Congress: Advancing Rheumatology for Europe's Future

The EULAR 2024 Congress in Vienna was held on June 12th-15th and brought together over 12,000 delegates,

 

offering a dynamic platform for sharing insights and innovations in rheumatology. With 136 scientific sessions led by 400 experts and a record 5,200 abstracts submitted, the congress highlighted significant advancements in understanding rheumatic and musculoskeletal diseases (RMDs).

A key focus was the unveiling of the EULAR Manifesto 2024–2029, advocating for a unified European strategy to tackle the health and socioeconomic impacts of RMDs. The Manifesto calls for innovative, cost-effective treatment models to address the growing burden of these diseases, particularly as Europe faces an ageing population. It provides a blueprint for improving care, research, and policies across the EU, with adaptable recommendations for member states.

Additionally, the first European patient-filled survey on the impact of RMDs was launched, aiming to gather crucial data to improve patient care and support advocacy efforts.

Finally, EULAR introduced the EULAR Network of Trial centers, creating a European network of clinical trial centers. This initiative seeks to facilitate impactful research that can drive meaningful changes in clinical practice, ultimately benefiting patients with RMDs. The EULAR 2024 Congress underscored the importance of collaboration, innovation, and patient-centered care in addressing the challenges of RMDs, setting the stage for a stronger future in European rheumatology.

Last modified on Thursday, 12 September 2024 06:49